摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-benzyl-3-(tert-butylsulfonyl)propionic acid | 114469-25-9

中文名称
——
中文别名
——
英文名称
2-benzyl-3-(tert-butylsulfonyl)propionic acid
英文别名
α-[[(1,1-dimethylethyl)sulfonyl]methyl]benzenepropanoic acid;2-Benzyl-3-(tert-butylsulfonyl)propanoic acid;2-benzyl-3-tert-butylsulfonylpropanoic acid
2-benzyl-3-(tert-butylsulfonyl)propionic acid化学式
CAS
114469-25-9
化学式
C14H20O4S
mdl
——
分子量
284.376
InChiKey
NVWAUJPSUAZNNS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    79.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    BUHLMAYER, PETER;CASELLI, ANTHONY;FUHRER, WALTER;GOSCHKE, RICHARD;RASETTI+, J. MED. CHEM., 31,(1988) N 9, C. 1839-1846
    摘要:
    DOI:
  • 作为产物:
    描述:
    乙基2-苄基丙烯酸酯盐酸oxone 、 sodium hydride 作用下, 以 乙醇溶剂黄146 为溶剂, 反应 72.0h, 生成 2-benzyl-3-(tert-butylsulfonyl)propionic acid
    参考文献:
    名称:
    Synthesis and biological activity of some transition-state inhibitors of human renin
    摘要:
    A series of renin inhibitors containing the dipeptide transition state mimics (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-7-methyloctanoic acid (Leu (OH)/Val) and (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-cyclohexylhexanoic acid (CHa /(OH)/Val) was prepared. A structure-activity study with Boc-Phe-His-Leu (OH)/Val-Ile-His-NH2 (8a) as starting material led to N-[(2S)-2-[(tert-butylsulfonyl)methyl]-3-phenylpropionyl]-His-Cha (OH)/ Val- NHC4H9-n (8i) which has the length of a tetrapeptide and contains only one natural amino acid. Compound 8i had an IC50 of 2 x 10(-9) M against human renin and showed high enzyme specificity; IC50 values against the related aspartic proteinases pepsin and cathepsin D were (8 x 10(-6) and 3 x 10(-6) M, respectively). In salt-depleted marmosets, 8i inhibited plasma renin activity PRA and lowered blood pressure for up to 2 h after oral administration of a dose of 10 mg/kg.
    DOI:
    10.1021/jm00117a027
点击查看最新优质反应信息

文献信息

  • Novel amino acid derivatives possessing renin-inhibitory activities
    申请人:Japan Tobacco Inc.
    公开号:EP0396065A1
    公开(公告)日:1990-11-07
    An amino acid derivative of the general formula: wherein R1 is wherein, R10 is a lower alkyl group and R" is (wherein R111 is a lower alkyl group and n is an integer of 1 to 5) or a lower alkyl group which may be substituted by hydroxy group or methoxyethoxymethoxy group, or R'° and R" are combinedly together with the adjacent nitrogen atom; R12 is a hydrogen atom, CnH2n+1-O-CO- (n is as defined above) or R'3 is a lower alkyl group which may be substituted by substituent(s) selected from HOOC-(H2C)n-O-, R12- NH- (n and R12 are as defined above) and pyridyl group; X is -CH2-, -O- or -NH- and Y is -O- or -NH-; wherein (wherein Z is -0-, -S-, -S(O)-. -S(O)2-, -CH2-, -CH(OH)-, or and a and b are independently an integer of 1 to 4 and the total of a and b is not more than 5) ; R2 is an aralkyl group which may be substituted by lower alkyl group(s); R3 is a hydrogen atom or a lower alkyl group; R4 is a lower alkyl group; and A is hydroxy group and B is a hydrogen atom, or A and B are carbonyl group combinedly together with the adjacent carbon atom, a pharmaceutically acceptable acid addition salt or an ester thereof is described. The compounds of the invention possess inhibitory activities against renin and are useful as an antihypertensive agent.
    通用公式的氨基酸衍生物: 其中R1为 其中,R10为较低的烷基基团,R"为 (其中R111为较低的烷基基团,n为1至5的整数)或者可以被羟基或甲氧乙氧甲氧基取代的较低烷基基团,或者R'°和R"与相邻的氮原子 结合在一起; R12为氢原子,CnH2n+1-O-CO-(n如上定义)或者 R'3为可以被HOOC-(H2C)n-O-、R12-NH-(n和R12如上定义)和吡啶基取代的较低烷基基团; X为-CH2-、-O-或-NH-,Y为-O-或-NH-;其中 (其中Z为-0-、-S-、-S(O)-、-S(O)2-、-CH2-、-CH(OH)-, 或 a和b分别独立为1至4的整数,且a和b的总和不超过5); R2为可以被较低烷基基团取代的芳基烷基基团; R3为氢原子或较低烷基基团; R4为较低烷基基团; A为羟基,B为氢原子,或者A和B与相邻的碳原子结合在一起,描述了一种药学上可接受的酸盐或其酯。本发明的化合物具有对肾素的抑制活性,并可用作降压药。
  • Renin-inhibiting functionalized peptidyl aminodiols and - triols
    申请人:ABBOTT LABORATORIES
    公开号:EP0341602A2
    公开(公告)日:1989-11-15
    A renin inhibiting compound of the formula: or a pharmaceutically acceptable salt, ester or prodrug thereof.
    一个公式为的抑制肾素的化合物: 或其药用可接受的盐、酯或前药。
  • Diol sulfonamide and sulfinyl renin inhibitors
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US05098924A1
    公开(公告)日:1992-03-24
    Compounds of the formula ##STR1## wherein Z is SO or SO.sub.2 possess renin inhibition activity and are useful in treating hypertension and other diseases where the reduction of the levels of circulating angiotensin II are beneficial.
    式为##STR1##的化合物,其中Z为SO或SO.sub.2,具有抑制肾素活性的作用,并可用于治疗高血压和其他减少循环中抗肾素II水平有益的疾病。
  • Peptidyl difluorodiol renin inhibitors
    申请人:ABBOTT LABORATORIES
    公开号:EP0416393A1
    公开(公告)日:1991-03-13
    A renin inhibiting compound of the formula: wherein A is a functional group; W is (1) -C(O)-, (2) -CH(OH)- or (3) -N(R₂)- wherein R₂ is hydrogen or loweralkyl; U is (1) -C(O)-, (2) -CH₂- or (3) -N(R₂)- wherein R₂ is hydrogen or lower alkyl, with the proviso that when W is -CH(OH)- then U is -CH₂- and with the proviso that U is -C(O)- or -CH₂- when W is -N(R₂)-; V is (1) -CH-, (2) -C(OH)- or (3) -C(halogen)- with the proviso that v is -CH-­when U is -N(R₂)-; Q is -CH(R₁)- or -C(=CHR1a)- wherein R₁ is (1) loweralkyl, (2) cycloalkylalkyl, (3) arylalkyl, (4) (heterocyclic)alkyl, (5) 1-benzyloxyethyl, (6) phenoxy, (7) thiophenoxy or (8) anilino, provided that B is -CH₂- or -CH(OH)- or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino and R1a is aryl or heterocyclic; R₃ is a functional group; R₄ is (1) loweralkyl, (2) cycloalkylmethyl or (3) benzyl; R₅ is -CH(OH)- or -C(O)-; R₆ is -CH(OH)- or -C(O)-; and Z is (1) lower alkyl, (2) aryl, (3) arylalkyl, (4) cycloalkyl, (5) cycloalkylalkyl, (6) heterocyclic or (7) (heterocyclic)alkyl; or a pharmaceutically acceptable salt, ester or prodrug thereof.
    一种肾素抑制化合物的化学式:其中A是一个功能基团;W是(1) -C(O)-,(2) -CH(OH)-或(3) -N(R₂)-,其中R₂是氢或较低烷基;U是(1) -C(O)-,(2) -CH₂-或(3) -N(R₂)-,其中R₂是氢或较低烷基,但当W为-CH(OH)-时,则U为-CH₂-,并且当U为-N(R₂)-时,U为-C(O)-或-CH₂-;V是(1) -CH-,(2) -C(OH)-或(3) -C(卤素)-,但当U为-N(R₂)-时,V为-CH-;Q是-CH(R₁)-或-C(=CHR1a)-,其中R₁是(1) 较低烷基,(2) 环烷基烷基,(3) 芳基烷基,(4) (杂环)烷基,(5) 1-苄氧乙基,(6) 苯氧基,(7) 噻吩氧基或(8) 氨基苯基,前提是当R₁是苯氧基、噻吩氧基或氨基苯基时,B是-CH₂-或-CH(OH)-,或A是氢,而R1a是芳基或杂环;R₃是一个功能基团;R₄是(1) 较低烷基,(2) 环烷基甲基或(3) 苄基;R₅是-CH(OH)-或-C(O)-;R₆是-CH(OH)-或-C(O)-;Z是(1) 较低烷基,(2) 芳基,(3) 芳基烷基,(4) 环烷基,(5) 环烷基烷基,(6) 杂环或(7) (杂环)烷基;或其药学上可接受的盐、酯或前药。
  • Renin-inhibiting peptidyl heterocycles
    申请人:ABBOTT LABORATORIES
    公开号:EP0307837A3
    公开(公告)日:1991-12-11
    A renin inhibiting compound of the formula: wherein A is a substituent; W is C=O, CHOH or NR₂ wherein R₂ is hydrogen or loweralkyl; U is C=O, CH₂ or NR₂ wherein R₂ is hydrogen or loweralkyl, with the proviso that when W is CHOH then U is CH₂ and with the proviso that U is C=O or CH₂ when W is NR₂; V is CH, C(OH) or C(halogen) with the proviso that V is CH when U is NR₂; R₁ is loweralkyl, cycloalkylalkyl, benzyl, (alpha, alpha)-dimethylbenzyl, 4-methoxybenzyl, halobenzyl, 4-hydroxybenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (unsubstituted heterocyclic)methyl, (substituted heterocyclic)methyl, phenethyl, 1-benzyloxyethyl, phenoxy, thiophenoxy or anilino, provided that B is CH₂ or CHOH or A is hydrogen when R₁ is phenoxy, thiophenoxy or anilino; R₃ is loweralkyl, loweralkenyl, ((alkoxy)alkoxy)alkyl, carboxyalkyl, (thioalkoxy)alkyl, azidoalkyl, aminoalkyl, (alkyl)aminoalkyl, dialkylaminoalkyl, (alkoxy)(alkyl)aminoalkyl, (alkoxy)aminoalkyl, benzyl or heterocyclic ring substituted methyl; R₄ is loweralkyl, cycloalkylmethyl or benzyl; R₅ is OH or NH₂; and Z is a substituent.Also disclosed are compositions for and a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.
    一种抑制肾素的化合物,其结构式为:其中A是取代基;W为C=O、CHOH或NR₂,其中R₂为氢或较低的烷基;U为C=O、CH₂或NR₂,其中R₂为氢或较低的烷基,但当W为CHOH时,U为CH₂,且当U为C=O或CH₂时,W为NR₂;V为CH、C(OH)或C(卤素),但当U为NR₂时,V为CH;R₁为较低的烷基、环烷基烷基、苄基、(α,α)-二甲基苄基、4-甲氧基苄基、卤代苄基、4-羟基苄基、(1-萘基)甲基、(2-萘基)甲基、(未取代的杂环)甲基、(取代的杂环)甲基、苯乙基、1-苄氧基乙基、苯氧基、硫代苯氧基或苯胺基,但当R₁为苯氧基、硫代苯氧基或苯胺基时,B为CH₂或CHOH或A为氢;R₃为较低的烷基、较低的烯基、((烷氧基)烷氧基)烷基、羧基烷基、(硫代烷氧基)烷基、叠氮基烷基、氨基烷基、(烷基)氨基烷基、二烷基氨基烷基、(烷氧基)(烷基)氨基烷基、(烷氧基)氨基烷基、苄基或取代的杂环环取代的甲基;R₄为较低的烷基、环烷基甲基或苄基;R₅为OH或NH₂;Z为取代基。还披露了用于治疗高血压的组合物、制备抑制肾素化合物的方法以及制备抑制肾素化合物的中间体的方法。
查看更多